Home / Health / New Blood Test Detects Deadly Throat Cancer Early
New Blood Test Detects Deadly Throat Cancer Early
16 Jan
Summary
- Prometel International's PromarkerEso blood test gets patent.
- Test aims to detect esophageal adenocarcinoma early.
- EAC has low survival rates, with many diagnosed late.
Proteomics International has achieved a significant milestone with the granting of a Canadian patent for its PromarkerEso blood test. This innovative diagnostic technology is designed to detect early signs of esophageal adenocarcinoma (EAC), an aggressive and often deadly form of throat cancer.
The PromarkerEso test represents a considerable advancement, offering a non-invasive method for early disease identification. Current diagnostic methods for EAC, a cancer frequently associated with chronic acid reflux, often involve more invasive endoscopic procedures. This new blood test promises to identify the disease at much earlier, more treatable stages.
Esophageal adenocarcinoma poses a significant global health threat, with survival rates falling dramatically when diagnosed late. In countries like the US, where GERD is prevalent, many cases are detected only in advanced stages, leading to grim prognoses and a limited lifespan for affected patients.
